Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 498

1.

Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.

Tan TZ, Rouanne M, Tan KT, Huang RY, Thiery JP.

Eur Urol. 2018 Sep 10. pii: S0302-2838(18)30619-5. doi: 10.1016/j.eururo.2018.08.027. [Epub ahead of print]

PMID:
30213523
2.

DNA Methylation Profiling of Breast Cancer Cell Lines along the Epithelial Mesenchymal Spectrum-Implications for the Choice of Circulating Tumour DNA Methylation Markers.

Le AV, Szaumkessel M, Tan TZ, Thiery JP, Thompson EW, Dobrovic A.

Int J Mol Sci. 2018 Aug 28;19(9). pii: E2553. doi: 10.3390/ijms19092553.

3.

Actin Cytoskeleton Remodeling Drives Breast Cancer Cell Escape from Natural Killer-Mediated Cytotoxicity.

Al Absi A, Wurzer H, Guerin C, Hoffmann C, Moreau F, Mao X, Brown-Clay J, Petrolli R, Casellas CP, Dieterle M, Thiery JP, Chouaib S, Berchem G, Janji B, Thomas C.

Cancer Res. 2018 Oct 1;78(19):5631-5643. doi: 10.1158/0008-5472.CAN-18-0441. Epub 2018 Aug 13.

PMID:
30104240
4.

Tricho-rhino-phalangeal syndrome 1 protein functions as a scaffold required for ubiquitin-specific protease 4-directed histone deacetylase 2 de-ubiquitination and tumor growth.

Wang Y, Zhang J, Wu L, Liu W, Wei G, Gong X, Liu Y, Ma Z, Ma F, Thiery JP, Chen L.

Breast Cancer Res. 2018 Aug 2;20(1):83. doi: 10.1186/s13058-018-1018-7.

5.

The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.

Antony J, Zanini E, Kelly Z, Tan TZ, Karali E, Alomary M, Jung Y, Nixon K, Cunnea P, Fotopoulou C, Paterson A, Roy-Nawathe S, Mills GB, Huang RY, Thiery JP, Gabra H, Recchi C.

EMBO Rep. 2018 Aug;19(8). pii: e45670. doi: 10.15252/embr.201745670. Epub 2018 Jun 15.

PMID:
29907679
6.

Integrated use of bioinformatic resources reveals that co-targeting of histone deacetylases, IKBK and SRC inhibits epithelial-mesenchymal transition in cancer.

Barneh F, Mirzaie M, Nickchi P, Tan TZ, Thiery JP, Piran M, Salimi M, Goshadrou F, Aref AR, Jafari M.

Brief Bioinform. 2018 May 2. doi: 10.1093/bib/bby030. [Epub ahead of print]

PMID:
29726962
7.

CD47 is a direct target of SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT.

Noman MZ, Van Moer K, Marani V, Gemmill RM, Tranchevent LC, Azuaje F, Muller A, Chouaib S, Thiery JP, Berchem G, Janji B.

Oncoimmunology. 2018 Feb 15;7(4):e1345415. doi: 10.1080/2162402X.2017.1345415. eCollection 2018.

PMID:
29632713
8.

TGFβ Promotes Genomic Instability after Loss of RUNX3.

Krishnan V, Chong YL, Tan TZ, Kulkarni M, Bin Rahmat MB, Tay LS, Sankar H, Jokhun DS, Ganesan A, Chuang LSH, Voon DC, Shivashankar GV, Thiery JP, Ito Y.

Cancer Res. 2018 Jan 1;78(1):88-102. doi: 10.1158/0008-5472.CAN-17-1178. Epub 2017 Oct 26.

PMID:
29074538
9.

Metastatic efficiency of tumour cells can be impaired by intraoperative cell salvage process: truth or conjecture?

Kumar N, Zaw AS, Kantharajanna SB, Khoo BL, Lim CT, Thiery JP.

Transfus Med. 2017 Oct;27 Suppl 5:327-334. doi: 10.1111/tme.12453. Epub 2017 Aug 23. Review.

PMID:
28833768
10.

Molecular characterization of breast cancer CTCs associated with brain metastasis.

Boral D, Vishnoi M, Liu HN, Yin W, Sprouse ML, Scamardo A, Hong DS, Tan TZ, Thiery JP, Chang JC, Marchetti D.

Nat Commun. 2017 Aug 4;8(1):196. doi: 10.1038/s41467-017-00196-1.

11.

New insights into the role of EMT in tumor immune escape.

Terry S, Savagner P, Ortiz-Cuaran S, Mahjoubi L, Saintigny P, Thiery JP, Chouaib S.

Mol Oncol. 2017 Jul;11(7):824-846. doi: 10.1002/1878-0261.12093. Epub 2017 Jun 27. Review.

12.

Clear Cell Renal Cell Carcinoma is linked to Epithelial-to-Mesenchymal Transition and to Fibrosis.

Landolt L, Eikrem Ø, Strauss P, Scherer A, Lovett DH, Beisland C, Finne K, Osman T, Ibrahim MM, Gausdal G, Ahmed L, Lorens JB, Thiery JP, Tan TZ, Sekulic M, Marti HP.

Physiol Rep. 2017 Jun;5(11). pii: e13305. doi: 10.14814/phy2.13305. Erratum in: Physiol Rep. 2018 Apr;6(8):e13671.

13.

The EMT spectrum and therapeutic opportunities.

Voon DC, Huang RY, Jackson RA, Thiery JP.

Mol Oncol. 2017 Jul;11(7):878-891. doi: 10.1002/1878-0261.12082. Epub 2017 Jun 19. Review.

14.

Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.

Yu S, Cai X, Wu C, Liu Y, Zhang J, Gong X, Wang X, Wu X, Zhu T, Mo L, Gu J, Yu Z, Chen J, Thiery JP, Chai R, Chen L.

Int J Biol Sci. 2017 Apr 8;13(4):505-517. doi: 10.7150/ijbs.18834. eCollection 2017.

15.

Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated cytotoxicity.

Terry S, Buart S, Tan TZ, Gros G, Noman MZ, Lorens JB, Mami-Chouaib F, Thiery JP, Chouaib S.

Oncoimmunology. 2017 Jan 17;6(2):e1271858. doi: 10.1080/2162402X.2016.1271858. eCollection 2017.

16.

The Emerging Roles of RUNX Transcription Factors in Epithelial-Mesenchymal Transition.

Voon DC, Thiery JP.

Adv Exp Med Biol. 2017;962:471-489. doi: 10.1007/978-981-10-3233-2_28. Review.

PMID:
28299674
17.

Data-Driven Discovery of Extravasation Pathway in Circulating Tumor Cells.

Yadavalli S, Jayaram S, Manda SS, Madugundu AK, Nayakanti DS, Tan TZ, Bhat R, Rangarajan A, Chatterjee A, Gowda H, Thiery JP, Kumar P.

Sci Rep. 2017 Mar 6;7:43710. doi: 10.1038/srep43710.

18.

Transposon insertional mutagenesis in mice identifies human breast cancer susceptibility genes and signatures for stratification.

Chen L, Jenjaroenpun P, Pillai AM, Ivshina AV, Ow GS, Efthimios M, Zhiqun T, Tan TZ, Lee SC, Rogers K, Ward JM, Mori S, Adams DJ, Jenkins NA, Copeland NG, Ban KH, Kuznetsov VA, Thiery JP.

Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2215-E2224. doi: 10.1073/pnas.1701512114. Epub 2017 Mar 1.

19.

The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200.

Noman MZ, Janji B, Abdou A, Hasmim M, Terry S, Tan TZ, Mami-Chouaib F, Thiery JP, Chouaib S.

Oncoimmunology. 2017 Jan 23;6(1):e1263412. doi: 10.1080/2162402X.2016.1263412. eCollection 2017.

20.

'Normalizing' the malignant phenotype of luminal breast cancer cells via alpha(v)beta(3)-integrin.

Abu-Tayeh H, Weidenfeld K, Zhilin-Roth A, Schif-Zuck S, Thaler S, Cotarelo C, Tan TZ, Thiery JP, Green JE, Klorin G, Sabo E, Sleeman JP, Tzukerman M, Barkan D.

Cell Death Dis. 2016 Dec 1;7(12):e2491. doi: 10.1038/cddis.2016.387.

21.

The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.

Antony J, Tan TZ, Kelly Z, Low J, Choolani M, Recchi C, Gabra H, Thiery JP, Huang RY.

Sci Signal. 2016 Oct 4;9(448):ra97.

22.

PRL3-zumab, a first-in-class humanized antibody for cancer therapy.

Thura M, Al-Aidaroos AQ, Yong WP, Kono K, Gupta A, Lin YB, Mimura K, Thiery JP, Goh BC, Tan P, Soo R, Hong CW, Wang L, Lin SJ, Chen E, Rha SY, Chung HC, Li J, Nandi S, Yuen HF, Zhang SD, Guan YK, So J, Zeng Q.

JCI Insight. 2016 Jun 16;1(9):e87607.

23.

Impact of label-free technologies in head and neck cancer circulating tumour cells.

Kulasinghe A, Kenny L, Perry C, Thiery JP, Jovanovic L, Vela I, Nelson C, Punyadeera C.

Oncotarget. 2016 Nov 1;7(44):71223-71234. doi: 10.18632/oncotarget.12086.

24.

TIP60 inhibits metastasis by ablating DNMT1-SNAIL2-driven epithelial-mesenchymal transition program.

Zhang Y, Subbaiah VK, Rajagopalan D, Tham CY, Abdullah LN, Toh TB, Gong M, Tan TZ, Jadhav SP, Pandey AK, Karnani N, Chow EK, Thiery JP, Jha S.

J Mol Cell Biol. 2016 Sep 20. pii: mjw038. [Epub ahead of print]

PMID:
27651430
25.

An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancers.

Tang HM, Kuay KT, Koh PF, Asad M, Tan TZ, Chung VY, Lee SC, Thiery JP, Huang RJ.

Cell Death Discov. 2016 Jun 13;2:16041. doi: 10.1038/cddiscovery.2016.41. eCollection 2016.

26.

Correction: RKIP regulates CCL5 expression to inhibit breast cancer invasion and metastasis by controlling macrophage infiltration.

Datar I, Qiu X, Ma HZ, Yeung M, Aras S, de la Serna I, Al-Mulla F, Tan TZ, Thiery JP, Trumbly R, Xuan F, Cui H, Yeung KC.

Oncotarget. 2016 May 3;7(18):26925. doi: 10.18632/oncotarget.9139.

27.

Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment.

Khoo BL, Grenci G, Jing T, Lim YB, Lee SC, Thiery JP, Han J, Lim CT.

Sci Adv. 2016 Jul 13;2(7):e1600274. doi: 10.1126/sciadv.1600274. eCollection 2016 Jul.

28.

Manganese Superoxide Dismutase Expression Regulates the Switch Between an Epithelial and a Mesenchymal-Like Phenotype in Breast Carcinoma.

Loo SY, Hirpara JL, Pandey V, Tan TZ, Yap CT, Lobie PE, Thiery JP, Goh BC, Pervaiz S, Clément MV, Kumar AP.

Antioxid Redox Signal. 2016 Aug 20;25(6):283-99. doi: 10.1089/ars.2015.6524.

29.

EMT: 2016.

Nieto MA, Huang RY, Jackson RA, Thiery JP.

Cell. 2016 Jun 30;166(1):21-45. doi: 10.1016/j.cell.2016.06.028. Review.

30.

TRPV4 Regulates Breast Cancer Cell Extravasation, Stiffness and Actin Cortex.

Lee WH, Choong LY, Mon NN, Lu S, Lin Q, Pang B, Yan B, Krishna VS, Singh H, Tan TZ, Thiery JP, Lim CT, Tan PB, Johansson M, Harteneck C, Lim YP.

Sci Rep. 2016 Jun 13;6:27903. doi: 10.1038/srep27903.

31.

Corrigendum to "Mach-Zehnder interferometer (MZI) point-of-care system for rapid multiplexed detection of microRNAs in human urine specimens" [Biosens. Bioelectron. 71 (2015) 365-372].

Liu Q, Shin Y, Kee JS, Kim KW, Mohamed Rafei SR, Perera AP, Tu X, Lo GQ, Ricci E, Colombel M, Chiong E, Thiery JP, Park MK.

Biosens Bioelectron. 2016 Nov 15;85:996. doi: 10.1016/j.bios.2016.05.011. Epub 2016 May 18. No abstract available.

PMID:
27208992
32.

Microfluidic models for adoptive cell-mediated cancer immunotherapies.

Adriani G, Pavesi A, Tan AT, Bertoletti A, Thiery JP, Kamm RD.

Drug Discov Today. 2016 Sep;21(9):1472-1478. doi: 10.1016/j.drudis.2016.05.006. Epub 2016 May 13. Review.

33.

Exosome-Mediated Metastasis: From Epithelial-Mesenchymal Transition to Escape from Immunosurveillance.

Syn N, Wang L, Sethi G, Thiery JP, Goh BC.

Trends Pharmacol Sci. 2016 Jul;37(7):606-617. doi: 10.1016/j.tips.2016.04.006. Epub 2016 May 3. Review.

PMID:
27157716
34.

Identification of 42 Genes Linked to Stage II Colorectal Cancer Metastatic Relapse.

Al-Temaimi RA, Tan TZ, Marafie MJ, Thiery JP, Quirke P, Al-Mulla F.

Int J Mol Sci. 2016 Apr 28;17(5). pii: E598. doi: 10.3390/ijms17050598.

35.

Erratum: Noncanonical roles of membranous lysyl-tRNA synthetase in transducing cell-substrate signaling for invasive dissemination of colon cancer spheroids in 3D collagen I gels.

Nam SH, Kim D, Lee MS, Lee D, Kwak TK, Kang M, Ryu J, Kim HJ, Song HE, Choi J, Lee GH, Kim SY, Park SH, Kim DG, Kwon NH, Kim TY, Thiery JP, Kim S, Lee JW.

Oncotarget. 2016 Feb 9;7(6):7367. doi: 10.18632/oncotarget.7117. No abstract available.

36.

Intraoperative cell salvage in metastatic spine tumour surgery reduces potential for reinfusion of viable cancer cells.

Kumar N, Zaw AS, Khoo BL, Nandi S, Lai Z, Singh G, Lim CT, Thiery JP.

Eur Spine J. 2016 Dec;25(12):4008-4015. Epub 2016 Mar 7.

PMID:
26951173
37.

GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification.

Chung VY, Tan TZ, Tan M, Wong MK, Kuay KT, Yang Z, Ye J, Muller J, Koh CM, Guccione E, Thiery JP, Huang RY.

Sci Rep. 2016 Feb 18;6:19943. doi: 10.1038/srep19943.

38.

Extracellular matrix scaffolding guides lumen elongation by inducing anisotropic intercellular mechanical tension.

Li Q, Zhang Y, Pluchon P, Robens J, Herr K, Mercade M, Thiery JP, Yu H, Viasnoff V.

Nat Cell Biol. 2016 Mar;18(3):311-8. doi: 10.1038/ncb3310. Epub 2016 Feb 15.

PMID:
26878396
39.

CSIOVDB: a microarray gene expression database of epithelial ovarian cancer subtype.

Tan TZ, Yang H, Ye J, Low J, Choolani M, Tan DS, Thiery JP, Huang RY.

Oncotarget. 2015 Dec 22;6(41):43843-52. doi: 10.18632/oncotarget.5983.

40.

Homophilic interaction and deformation of E-cadherin and cadherin 7 probed by single molecule force spectroscopy.

Wu F, Kumar P, Lu C, El Marjou A, Qiu W, Lim CT, Thiery JP, Liu R.

Arch Biochem Biophys. 2015 Dec 1;587:38-47. doi: 10.1016/j.abb.2015.10.008. Epub 2015 Oct 24.

PMID:
26476343
41.

Identification of drugs as single agents or in combination to prevent carcinoma dissemination in a microfluidic 3D environment.

Bai J, Tu TY, Kim C, Thiery JP, Kamm RD.

Oncotarget. 2015 Nov 3;6(34):36603-14. doi: 10.18632/oncotarget.5464.

42.

RKIP regulates CCL5 expression to inhibit breast cancer invasion and metastasis by controlling macrophage infiltration.

Datar I, Qiu X, Ma HZ, Yeung M, Aras S, de la Serna I, Al-Mulla F, Thiery JP, Trumbly R, Fan X, Cui H, Yeung KC.

Oncotarget. 2015 Nov 17;6(36):39050-61. doi: 10.18632/oncotarget.5176. Erratum in: Oncotarget. 2016 May 3;7(18):26925.

43.

Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.

Chua KN, Kong LR, Sim WJ, Ng HC, Ong WR, Thiery JP, Huynh H, Goh BC.

Oncotarget. 2015 Oct 6;6(30):29991-30005. doi: 10.18632/oncotarget.5031.

44.

Contact-dependent carcinoma aggregate dispersion by M2a macrophages via ICAM-1 and β2 integrin interactions.

Bai J, Adriani G, Dang TM, Tu TY, Penny HX, Wong SC, Kamm RD, Thiery JP.

Oncotarget. 2015 Sep 22;6(28):25295-307. doi: 10.18632/oncotarget.4716.

45.

Noncanonical roles of membranous lysyl-tRNA synthetase in transducing cell-substrate signaling for invasive dissemination of colon cancer spheroids in 3D collagen I gels.

Nam SH, Kim D, Lee MS, Lee D, Kwak TK, Kang M, Ryu J, Kim HJ, Song HE, Choi J, Lee GH, Kim SY, Park SH, Kim DG, Kwon NH, Kim TY, Thiery JP, Kim S, Lee JW.

Oncotarget. 2015 Aug 28;6(25):21655-74. Erratum in: Oncotarget. 2016 Feb 9;7(6):7367.

46.
47.

Chronic chemotherapeutic stress promotes evolution of stemness and WNT/beta-catenin signaling in colorectal cancer cells: implications for clinical use of WNT-signaling inhibitors.

Ayadi M, Bouygues A, Ouaret D, Ferrand N, Chouaib S, Thiery JP, Muchardt C, Sabbah M, Larsen AK.

Oncotarget. 2015 Jul 30;6(21):18518-33.

48.

Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy.

Khoo BL, Lee SC, Kumar P, Tan TZ, Warkiani ME, Ow SG, Nandi S, Lim CT, Thiery JP.

Oncotarget. 2015 Jun 20;6(17):15578-93.

49.

Mach-Zehnder interferometer (MZI) point-of-care system for rapid multiplexed detection of microRNAs in human urine specimens.

Liu Q, Shin Y, Kee JS, Kim KW, Mohamed Rafei SR, Perera AP, Tu X, Lo GQ, Ricci E, Colombel M, Chiong E, Thiery JP, Park MK.

Biosens Bioelectron. 2015 Sep 15;71:365-372. doi: 10.1016/j.bios.2015.04.052. Epub 2015 Apr 20. Erratum in: Biosens Bioelectron. 2016 Nov 15;85:996.

PMID:
25950930
50.

MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma.

Kong LR, Chua KN, Sim WJ, Ng HC, Bi C, Ho J, Nga ME, Pang YH, Ong WR, Soo RA, Huynh H, Chng WJ, Thiery JP, Goh BC.

Mol Cancer Ther. 2015 Jul;14(7):1750-60. doi: 10.1158/1535-7163.MCT-15-0062. Epub 2015 May 4.

Supplemental Content

Loading ...
Support Center